keyword
MENU ▼
Read by QxMD icon Read
search

JNCI

keyword
https://www.readbyqxmd.com/read/30275983/reported-use-of-reporting-guidelines-among-jnci-journal-of-the-national-cancer-institute-authors-editorial-outcomes-and-reviewer-ratings-related-to-adherence-to-guidelines-and-clarity-of-presentation
#1
Jeannine Botos
Background: Associations were examined between author-reported uses of reporting guidelines to prepare JNCI: Journal of the National Cancer Institute ( JNCI ) submissions, editorial decisions, and reviewer ratings for adherence to reporting guidelines and clarity of presentation. Methods: At submission, authors were asked if they used reporting guidelines to prepare their manuscript and, if so, which one(s). Reviewers rated adherence to reporting guidelines and clarity of presentation...
2018: Research Integrity and Peer Review
https://www.readbyqxmd.com/read/28159496/androgen-deprivation-with-or-without-radiation-therapy-for-clinically-node-positive-prostate-cancer-lin-cc-gray-pj-jemal-a-efstathiou-ja-surveillance-and-health-services-research-program-intramural-research-american-cancer-society-atlanta-ga-ccl-aj-department
#2
Eggener Scott
BACKGROUND: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base. METHODS: Patients with cN+PCa and without distant metastases diagnosed between 2004 and 2011 were included...
March 2017: Urologic Oncology
https://www.readbyqxmd.com/read/26286731/the-role-of-multidrug-resistance-efflux-pumps-in-cancer-revisiting-a-jnci-publication-exploring-expression-of-the-mdr1-p-glycoprotein-gene
#3
Michael M Gottesman, Ira H Pastan
No abstract text is available yet for this article.
September 2015: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/25928630/a-systematic-review-and-meta-analysis-to-compare-the-efficacy-of-acyclovir-3-ophthalmic-ointment-to-idoxuridine-in-curing-herpetic-keratitis-by-day-7-of-treatment
#4
REVIEW
Diane E Balderson, Gengqian Cai, Michael A Fries, David M Kleinman, Megan M McLaughlin, Trupti M Trivedi, John I Wurzelmann, Sheila B Young
BACKGROUND: This objective of the review and analysis is to demonstrate that acyclovir (ACV) 3% ophthalmic ointment is superior to idoxuridine (IDU) in treating herpetic keratitis (HK) presenting as dendritic and geographic ulcer sub-types. METHODS: HASH(0x4c507a0) DATA SOURCES: Publications in human subjects were identified by searching the Ovid MEDLINE database through April 2011, combining medical subject headings (MESH) "Keratitis, Herpetic/" AND "Acyclovir/" limiting by the key words "topical" OR "ointment" and also restricted to MESH "Administration, Topical/" OR "Ointments/"...
2015: BMC Ophthalmology
https://www.readbyqxmd.com/read/25713150/jnci-and-cancer-prevention
#5
Barbara K Dunn, Sharmistha Ghosh, Barnett S Kramer
The Journal of the National Cancer Institute (JNCI), with its broad coverage of bench research, epidemiologic studies, and clinical trials, has a long history of publishing practice-changing studies in cancer prevention and public health. These include studies of tobacco cessation, chemoprevention, and nutrition. The landmark Breast Cancer Prevention Trial (BCPT)-the first large trial to prove efficacy of a preventive medication for a major malignancy-was published in the Journal, as were key ancillary papers to the BCPT...
March 2015: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/25564599/jnci-is-75-years-old
#6
EDITORIAL
Carmen J Allegra, Jeannine Botos
No abstract text is available yet for this article.
January 2015: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/25087670/commentary-on-predicted-plasma-25-hydroxyvitamin-d-and-risk-of-renal-cell-cancer-joh-hk-giovannucci-el-bertrand-ka-lim-s-cho-e-department-of-medicine-seoul-national-university-college-of-medicine-seoul-south-korea-j-natl-cancer-inst-2013-105-10-726-32-epub
#7
COMMENT
Stephen Boorjian
BACKGROUND: Although the kidney is a primary organ for vitamin D metabolism, the association between vitamin D and renal cell cancer (RCC) remains unclear. METHODS: We prospectively evaluated the association between predicted plasma 25-hydroxyvitamin D [25(OH)D] and RCC risk among 72,051 women and 46,380 men in the period from 1986 to 2008. Predicted plasma 25(OH)D scores were computed using validated regression models that included major determinants of vitamin D status (race, ultraviolet B flux, physical activity, body mass index, estimated vitamin D intake, alcohol consumption, and postmenopausal hormone use in women)...
August 2014: Urologic Oncology
https://www.readbyqxmd.com/read/24326015/cancer-immunotherapy-are-we-there-yet
#8
Zihai Li, Lieping Chen, Mark P Rubinstein
The immune system is the built-in host defense mechanism against infectious agents as well as cancer. Protective immunity against cancer was convincingly demonstrated in the 1940s with syngeneic animal models (JNCI 18:769-778, 1976; Cancer Immun 1:6, 2001). Since then, the last century's dream has been to effectively prevent and cure cancers by immunological means. This dream has slowly but surely become a reality (Nature 480:480-489, 2011). The successful examples of immunoprophylaxis and therapy against cancers include: (i) targeted therapy using monoclonal antibodies (Nat Rev Cancer 12:278-287, 2012); (ii) allogeneic hematopoietic stem cell transplantion to elicit graft-versus-cancer effect against a variety of hematopoietic malignancies (Blood 112:4371-4383, 2008); (iii) vaccination for preventing cancers with clear viral etiology such as hepatocellular carcinoma and cervical cancer (Cancer J Clin 57:7-28, 2007; NEJM 336:1855-1859, 1997); (iv) T cell checkpoint blockade against inhibitory pathways including targeting CTLA-4 and PD-1 inhibitory molecules for the treatment of melanoma and other solid tumors (NEJM 363:711-723, 2010; NEJM 366:2443-2454, 2012; NEJM 369:122-133, 2013; NEJM 366:2455-2465, 2012); (v) antigen-pulsed autologous dendritic cell vaccination against prostate cancer (NEJM 363:411-422, 2010); and (vi) the transfer of T cells including those genetically engineered with chimeric antigen receptors allowing targeting of B cell neoplasms (NEJM 365:725-733, 2011; NEJM 368:1509-1518, 2013; Blood 118:4817-4828, 2013; Sci Transl Med 5:177ra138, 2013)...
December 10, 2013: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/23820253/statin-use-in-primary-inflammatory-breast-cancer-a-cohort-study
#9
T M Brewer, H Masuda, D D Liu, Y Shen, P Liu, T Iwamoto, K Kai, C M Barnett, W A Woodward, J M Reuben, P Yang, G N Hortobagyi, N T Ueno
BACKGROUND: Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied. METHODS: We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin))...
July 23, 2013: British Journal of Cancer
https://www.readbyqxmd.com/read/22553474/abc1-consensus-conference-a-german-perspective-first-international-consensus-conference-on-advanced-breast-cancer-abc1-lisbon-november-5-2011
#10
Christoph Thomssen, Norbert Marschner, Michael Untch, Thomas Decker, Susanna Hegewisch-Becker, Christian Jackisch, Wolfgang Janni, Lück Hans-Joachim, Gunter von Minckwitz, Anton Scharl, Andreas Schneeweiss, Hans Tesch, Anja Welt, Nadia Harbeck
A group of German breast cancer experts (medical oncologists and gynaecologists) reviewed and commented on the results of the first international 'Advanced Breast Cancer First Consensus Conference' (ABC1) for the diagnosis and treatment of advanced breast cancer. The ABC1 Conference is an initiative of the European School of Oncology (ESO) Metastatic Breast Cancer Task Force in cooperation with the EBCC (European Breast Cancer Conference), ESMO (European Society of Medical Oncology) and the American JNCI (Journal of the National Cancer Institute)...
February 2012: Breast Care
https://www.readbyqxmd.com/read/21331279/characterization-of-published-errors-in-high-impact-oncology-journals
#11
A Molckovsky, M M Vickers, P A Tang
PURPOSE: To assess the frequency and propagation rate of published errors in the oncology literature and to determine possible contributing factors. METHODS: We reviewed 10 major oncology journals to determine variability in the online presentation of errata. Canadian oncologists were surveyed regarding characteristics that may influence error propagation. Errors published during 2004-2007 in the Journal of Clinical Oncology (jco) and the Journal of the National Cancer Institute (jnci) were classified as trivial or serious (that is, whether change in outcome was involved)...
January 2011: Current Oncology
https://www.readbyqxmd.com/read/20410466/adequacy-of-published-oncology-randomized-controlled-trials-to-provide-therapeutic-details-needed-for-clinical-application
#12
Jennifer M Duff, Helen Leather, Edmund O Walden, Kourtney D LaPlant, Thomas J George
BACKGROUND: Randomized controlled trials (RCTs) improve clinical care through evidence-based results. Guidelines exist for RCT result reporting, but specific details of therapeutic administration promote clinical application and reproduction of the trial design. We assess the reporting methodology in RCTs published in major oncology journals. METHODS: Ten essential elements of RCT reporting were identified and included drug name, dose, route, cycle length, maximum number of cycles, premedication, growth factor support, patient monitoring parameters, and dosing adjustments for hematologic and organ-specific toxicity...
May 19, 2010: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/20175033/modified-recist-mrecist-assessment-for-hepatocellular-carcinoma
#13
REVIEW
Riccardo Lencioni, Josep M Llovet
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis...
February 2010: Seminars in Liver Disease
https://www.readbyqxmd.com/read/18718690/choosing-the-best-endpoint
#14
COMMENT
Erik Christensen
Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; for the Panel of Experts in HCC-Design Clinical Trials. The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many patients have concurrent liver disease, which can confound the assessment of clinical benefit. There is an urgent need for high-quality trials in this disease. An expert panel was convened by the American Association for the Study of Liver Diseases to develop guidelines that provide a common framework for designing trials to facilitate comparability of results...
October 2008: Journal of Hepatology
https://www.readbyqxmd.com/read/17192041/repair-of-the-oxidative-dna-damage-8-oxoguanine-as-a-biomarker-for-lung-cancer-risk
#15
REVIEW
Tamar Paz-Elizur, Meir Krupsky, Dalia Elinger, Edna Schechtman, Zvi Livneh
DNA repair has a major role in suppressing the rate of accumulation of mutations. Therefore, variations in DNA repair are likely to play an important role in determining cancer risk. While there is compelling evidence that defects in DNA repair cause high predisposition to several hereditary cancers, there is a paucity of data on the role of DNA repair in sporadic cancers. We present our approach of using functional DNA repair tests, rather than gene polymorphism, to study the potential of DNA repair enzymes to serve as biomarkers for lung cancer risk...
2005: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/16997365/ernst-wynder-citation-analysis
#16
Steven D Stellman
Ernst Wynder published nearly 800 papers during his lifetime. I used the ISI Web of Science to analyze his publications and the subsequent literature citing his work. More than half of his papers were published in just ten journals, including Cancer, Preventive Medicine (which he founded and edited), JNCI, and Cancer Research. The 87 papers in Cancer covered all of the major cancer sites including breast, colon, lung, and prostate, and many others. Twenty-five papers and one book were cited in over 200 publications...
October 2006: Preventive Medicine
https://www.readbyqxmd.com/read/16775185/macrophage-inhibitory-cytokine-1-h6d-polymorphism-prostate-cancer-risk-and-survival
#17
Vanessa M Hayes, Gianluca Severi, Melissa C Southey, Emma J D Padilla, Dallas R English, John L Hopper, Graham G Giles, Robert L Sutherland
Macrophage inhibitory cytokine-1 (MIC-1), a member of the transforming growth factor-beta superfamily, is important in regulating inflammation. Inflammation of the prostate has been suggested to favor tumor development. A recent study (JNCI 2004, 96:1248-1254) found marginal evidence of an association between the presence of the mature MIC-1 protein nonsynonymous polymorphism H6D C-to-G (rs1058587) with reduced prostate cancer risk [odds ratio, 0.83; 95% confidence interval (95% CI), 0.69-0.99]. We tested this in a population-based study of 819 cases and 731 controls from Australia and found a similar, yet not significant, odds ratio of 0...
June 2006: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/15713968/lessons-from-controversy-ovarian-cancer-screening-and-serum-proteomics
#18
COMMENT
David F Ransohoff
In 2002 a study reported that a blood test, based on pattern-recognition proteomics mass spectroscopy analysis of serum, was nearly 100% sensitive and specific to detect ovarian cancer. Plans to introduce a commercial screening test by early 2004 were delayed amid concerns about whether the approach was reproducible and reliable. In this issue of JNCI, two commentaries discuss whether the initial results are reproducible and whether bias may account for results. This essay describes how threats to validity from chance and bias may cause erroneous results and inflated expectations in the kind of observational research being conducted in several "-omics" fields to assess molecular markers for diagnosis and prognosis of cancer...
February 16, 2005: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/12820437/single-agent-vinorelbine-as-first-line-chemotherapy-in-elderly-patients-with-advanced-breast-cancer
#19
REVIEW
Antonio Rossi, Cesare Gridelli, Vittorio Gebbia, Gerardo Rosati, Anna Tortoriello, Paolo Maione, Nicola Borsellino, Nestore Rossi, Agata Pisano, Giuseppe Colantuoni, Rosario Vincenzo Iaffaioli, Vincenzo Castaldo, Luigi Manzione
BACKGROUND: Breast cancer arises in about 48% of patients (pts) older than 65 years. Chemotherapy is administered to elderly pts with advanced breast cancer (ABC) resistant to hormonal treatment or with visceral metastases. Vinorelbine (VNR), a semisynthetic vinca alkaloid, is active and well-tolerated in ABC reporting, as a single agent, an objective response (OR) rate of 41%-60%. The ELVIS (Elderly Lung cancer Vinorelbine Italian Study) trial demonstrated the tolerability and efficacy of VNR in elderly pts with advanced non-small cell lung cancer (JNCI 91: 66-72, 1999)...
March 2003: Anticancer Research
https://www.readbyqxmd.com/read/12772191/recombinant-prostate-specific-antigen-inhibits-angiogenesis-in-vitro-and-in-vivo
#20
A H Fortier, J W Holaday, H Liang, C Dey, D K Grella, J Holland-Linn, H Vu, S M Plum, B J Nelson
BACKGROUND: Prostate specific antigen (PSA) is a kallikrein family member with serine protease activity commonly used as a diagnostic marker for prostate cancer. We recently described anti-angiogenic properties of PSA [Fortier et al.: JNCI 91:1635-1640]. METHODS: Two forms of PSA were cloned and expressed in Pichia pastoris: one, an intact PSA with an N-terminus of IVGGVS em leader; the second, an N-1 PSA variant. The recombinant proteins were tested for serine protease activity and for anti-angiogenic activity in vitro and in vivo...
August 1, 2003: Prostate
keyword
keyword
168151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"